Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression
Plans for global regulatory submissions are
- Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression
- Plans for global regulatory submissions are underway